57180-99-1

Upstream product

• 126989-04-6 p-Cyanbenzyliden-malonsaeurediethylester 
• 17201-43-3 4-cyanobenzyl bromide 
• 105-53-3 diethyl malonate 
• 104-85-8 para-methylbenzonitrile 

Downstream Products

• 124659-20-7 4-(2,4-Dioxo-1,5,9-triaza-cyclododec-3-ylmethyl)-benzonitrile 
• 112936-14-8 6-(4-cyanobenzyl)-1,4,8,11-tetra-azacyclotetradecan-5,7-dione 
• 129227-92-5 12-(4-cyanobenzyl)-1,4,7,10-tetraazacyclotridecan-11,13-dione 
• 112936-12-6 6-(4-aminomethylbenzyl)-1,4,8,11-tetra-azacyclotetradecane 
• 112936-13-7 2-ethenyl-6-<4-hydroxy-3-(1,4,8,11-tetra-azacyclotetradecan-5-yl)benzylcarbamoylmethoxymethyl>pyridine 
• 1211547-66-8 C₂₅H₃₇NO₅Si 
• 1094200-66-4 monoethyl (4-cyanobenzyl)malonate 
• 122497-11-4 2-ethenyl-6-<4-hydroxy-3-(1,4,7,10-tetra-azacyclotridecan-11-yl-benzyl)carbamoylmethoxymethyl>pyridine 
• 122497-09-0 12-(4-aminomethylbenzyl)-1,4,7,10-tetraazacyclotridecane 
• 124659-34-3 {3-[4-(Acetylamino-methyl)-benzyl]-5,9-bis-ethoxycarbonylmethyl-1,5,9-triaza-cyclododec-1-yl}-acetic acid ethyl ester 
• 124659-35-4 3-para-Aminomethylbenzyl-1,5,9-triazacyclododecane-N,N',N-triacetic acid 
• 124659-21-8 4-[2,4-Dioxo-9-(toluene-4-sulfonyl)-1,5,9-triaza-cyclododec-3-ylmethyl]-benzonitrile 
• 124659-22-9 4-[9-(Toluene-4-sulfonyl)-1,5,9-triaza-cyclododec-3-ylmethyl]-benzylamine 
• 124659-33-2 N-[4-(1,5,9-Triaza-cyclododec-3-ylmethyl)-benzyl]-acetamide 

Relevant academic research and scientific papers

HYDRIDE TRANSFER IN THE REDUCTION OF SUBSTITUTED BENZYLIDENE MALONIC DIESTERS BY COENZYME NAD(P)H MODEL

The reduction of substituted benzylidene malonic diesters by 1-benzyl-1,4-dihydronicotinamide (BNAH) is catalyzed by magnesium perchlorate.Kinetic isotope effects studies show that the C(4)-H bond cleavage in BNAH is involved in the rate determining step.Spectroscopic investigations have revealed that the ternary complex is formed in the ground state while complexation of substrate with magnesium ion is rate enhancing.

Aryltrifluoromethylative cyclization of unactivated alkenes by the use of PhICF3Cl under catalyst-free conditions

A concise and catalyst-free aryltrifluoromethylative cyclization of unactivated alkenes has been developed herein. The use of PhICF3Cl as a powerful trifluoromethylating agent allows easy transformations. A set of trifluoroethylated carbocycles and aza-hereocycles were efficiently synthesized in good yield and selectivity. A broad substrate scope, mild reaction conditions, and easy operation would make this method well-suited for applications.

Overturning established chemoselectivities: Selective reduction of arenes over malonates and cyanoacetates by photoactivated organic electron donors

The prevalence of metal-based reducing reagents, including metals, metal complexes, and metal salts, has produced an empirical order of reactivity that governs our approach to chemical synthesis. However, this reactivity may be influenced by stabilization of transition states, intermediates, and products through substrate-metal bonding. This article reports that in the absence of such stabilizing interactions, established chemoselectivities can be overthrown. Thus, photoactivation of the recently developed neutral organic superelectron donor 5 selectively reduces alkyl-substituted benzene rings in the presence of activated esters and nitriles, in direct contrast to metal-based reductions, opening a new perspective on reactivity. The altered outcomes arising from the organic electron donors are attributed to selective interactions between the neutral organic donors and the arene rings of the substrates.

EP2/4 AGONISTS

EP2/4 compounds having improved dual pharmacological activity are described. The uniqueness of using EP2/4 dual agonists resides in their ability to modify both uveoscleral outflow via the ciliary muscle and conventional outflow via trabecular meshwork and Schlemm's canal all in the same treatment paradigm. The compounds can be employed for the treatment of glaucoma and ocular hypertension. Formula (I).

NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF

The present invention provides a novel compound having an agonist action at AT2 receptor and expected as a pharmaceutical product, and also provides a method of treating or preventing various diseases. The novel sulfonyl malonamide derivative,

Modified pyrimidine glucocorticoid receptor modulators

The present invention provides a novel class of modified pyrimidine compounds and compositions and methods of using the compounds as glucocorticoid receptor modulators.

Towards Tumor Targeting with Copper-radiolabelled Macrocycle-Antibody Conjugates: Synthesis, Antibody Linkage, and Complexation Behaviour

A set of four tetra-azamacrocyclic ligands bearing aminomethylphenyl substituents have been prepared and may be attached to a monoclonal antibody via an intermediate thiol-specific vinylpyridine linker molecule.The resultant conjugates may be efficiently